General Information:

Id: 4,276 (click here to show other Interactions for entry)
Diseases: Diabetes mellitus, type II - [OMIM]
Insulin resistance
Schizophrenia - [OMIM]
Homo sapiens
Reference: Cabaleiro T et al.(2013) Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects Hum Psychopharmacol 28: 205-214 [PMID: 23559402]

Interaction Information:

Comment Olanzapine is a selective monoaminergic antagonist with high affinity binding to the following receptors: serotonin 5HT2A/2C; dopamine D1, D2, D3, and D4; muscarinic M1, M2, M3, M4, and M5; histamine H1; and adrenergic (alpha-1) receptors. The antipsychotic activity of olanzapine is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism of muscarinic, histamine, and adrenergic receptors may explain some adverse effects, such as anticholinergic effects, somnolence, and hypotension. (cited information)
Formal Description
Interaction-ID: 43747

drug/chemical compound


decreases_activity of



Drugbank entries Show/Hide entries for Olanzapine or DRD2